Neuronal ALKAL2 and its ALK receptor contribute to the development of colitis-associated colorectal cancer
Proceedings of the National Academy of Sciences · 2025
DOI: 10.1073/pnas.2500632122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Mélissa Delanne-Cuménal und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N4N1, Canada. Hauptthemen laut MEDLINE: Anaplastic Lymphoma Kinase, Colorectal Neoplasms, Colitis-Associated Neoplasms, Colitis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Canadian Government | Canadian Institutes of Health Research (CIHR).
Abstract (Originalsprache)
Tumor-infiltrating nerves play a critical role in cancer progression and treatment resistance. Our recent work identified ALKAL2, a ligand for the Anaplastic Lymphoma Kinase (ALK) receptor, as a key mediator of inflammatory pain, with its expression significantly elevated in TRPV1+ sensory neurons during inflammation. Here, we explored the regulation of neuronal ALKAL2 in a colitis-associated colorectal cancer (CAC) model. We found that neuronal ALKAL2 is upregulated at early stages of CAC, which in turn activates ALK signaling in the colonic mucosa. Notably, treating mouse colonic organoids with exogenous ALKAL2 triggered ALK activation. In vivo, mice treated with the ALK inhibitor lorlatinib at the onset of colitis exhibited a remarkable 90% reduction in tumor burden without significantly affecting overall inflammation. Moreover, activating TRPV1+ neurons using DREADD technology exacerbated tumor growth, whereas silencing these neurons significantly reduced it. These findings reveal that TRPV1+ nociceptors drive CAC progression via the ALKAL2/ALK pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N4N1, Canada.
- Department of Physiology and Pharmacology, Inflammation Research Network-Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, AB T2N4N1, Canada.
- Department of Physiology and Pharmacology, Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB T2N4N1, Canada.
- Department of Physiology and Pharmacology, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, AB T2N4N1, Canada.
- Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, AB T2N4N1, Canada.
- Department of Pharmacology, Yale University School of Medicine, New Haven, CT 0620.
ORCID-Profile: Joseph Schlessinger, Christophe Altier
Förderung
- Canadian Government | Canadian Institutes of Health Research (CIHR)
Zitieren
APA
Delanne-Cuménal, M., Defaye, M., Delanne-Cuménal, A., Ahmed, M., Ho, V., Abdullah, N. S., Alhassoun, M., Svendsen, K., Mager, L., Schlessinger, J., Hirota, S., & Altier, C. (2025). Neuronal ALKAL2 and its ALK receptor contribute to the development of colitis-associated colorectal cancer. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2500632122
Vancouver
Delanne-Cuménal M, Defaye M, Delanne-Cuménal A, Ahmed M, Ho V, Abdullah NS, et al. Neuronal ALKAL2 and its ALK receptor contribute to the development of colitis-associated colorectal cancer. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2500632122
BibTeX
@article{DelanneCumnal2025,
author = {Delanne-Cuménal, Mélissa and Defaye, Manon and Delanne-Cuménal, Améline and Ahmed, Mansoor and Ho, Valerie and Abdullah, Nasser S and Alhassoun, Mohamad and Svendsen, Kristofer and Mager, Lukas and Schlessinger, Joseph and Hirota, Simon and Altier, Christophe},
title = {Neuronal ALKAL2 and its ALK receptor contribute to the development of colitis-associated colorectal cancer},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
doi = {10.1073/pnas.2500632122}
}
EUVIMED